Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Pacira BioSciences (PCRX)

Pacira Q2 revenue rises to $181.1 million; net loss $4.8 million, guidance narrowed

Mixed Impact 4 of 5 earnings Written later

Pacira BioSciences reported second-quarter 2025 total revenue of $181.1 million, up from $178.0 million a year earlier, but swung to a GAAP net loss of $4.8 million from net income of $18.9 million. The company narrowed its full-year 2025 revenue guidance to $730 million to $750 million and raised its non-GAAP gross margin guidance to 78 to 80 percent, while non-GAAP net income and adjusted EBITDA both declined year over year.

Key points

  • Total revenue $181.1 million versus $178.0 million in Q2 2024; EXPAREL net product sales $142.9 million.
  • GAAP net loss of $4.8 million, or $0.11 per share, versus GAAP net income of $18.9 million, or $0.41 per share (basic), in Q2 2024.
  • Non-GAAP net income $36.0 million, or $0.74 per share (diluted), versus $44.2 million, or $0.89 per share (diluted), a year earlier.
  • Full-year 2025 revenue guidance narrowed to $730 million to $750 million from $725 million to $765 million; non-GAAP gross margin guidance raised to 78 to 80 percent from 76 to 78 percent.

The filing

CompanyPacira BioSciences (PCRX)
Form8-K, current report
Filed with the SECAug 5, 2025, 4:01 PM ET
Accession number0001396814-25-000100

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:58 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.